Serum insulin level, HOMA-IR and prostate cancer risk: A systematic review and meta-analysis.

Abstract

AIMS\nThis meta-analysis study was performed to assess serum insulin level and insulin resistance status in prostate cancer patients in observational studies.\n\n\nMATERIALS AND METHODS\nA systematic literature search was performed for observational studies in Scopus, PubMed, Ovid and ISI Web of Science up to July 2017.\n\n\nRESULTS\nFrom 2070 publication were searched firstly, only 10 studies with 9 and 6 arms included for the meta-analysis assessing serum insulin level and HOMA-IR status in prostate cancer patients, respectively. Pooled effects analysis showed that the Fasting insulin level was significantly higher in men with prostate cancer compared to control group (WMD\u202f=\u202f2.12 μ IU/ml, 95%CI; 0.26, 3.99; P\u202f=\u202f0.02). Sub-group analysis showed that the elevation in serum insulin level takes place only in patients with ages more than 65 years old (WMD\u202f=\u202f3.88 μ IU/ml, 95%CI; 2.28, 5.48; P\u202f<\u202f0.001). HOMA-IR was no significantly different between study groups. However, the difference got statistically significant after sub-grouping patients based on their age (WMD\u202f=\u202f1.37, 95% CI; 0.61, 2.12; P\u202f<\u202f0.001).\n\n\nCONCLUSION\nIn conclusion, the results of this meta-analysis study showed higher fasting serum insulin and HOMA-IR levels especially in patients with ages more than 65 years..